Premium
Patient‐reported outcomes enhance understanding of the impact of pazopanib in soft tissue sarcoma
Author(s) -
Gotay Carolyn
Publication year - 2015
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.29429
Subject(s) - pazopanib , medicine , soft tissue sarcoma , quality of life (healthcare) , soft tissue , global health , sarcoma , overall survival , intensive care medicine , cancer , oncology , surgery , pathology , public health , nursing , sunitinib
The primary conclusion of this study—that increased progression‐free survival is associated with more symptoms but not with compromised global health‐related quality of life (global health status)—has important implications. A more fine‐grained approach is necessary to understand more about why patients rate their global health status as they do and how they interpret and explain their symptom experience.